George Vrachiolias

Dr. George Vrachiolias

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2020 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
KLKonstantinos Liapis
Konstantinos Liapis
MPMenelaos Papoutselis
Menelaos Papoutselis
GVGeorge Vrachiolias
George Vrachiolias
CMChristina Misidou
Christina Misidou
ESEmmanouil Spanoudakis
Emmanouil Spanoudakis
IKIoannis Kotsianidis
Ioannis Kotsianidis

1 July 2020 in eJHaem
Verified
Journal Article
Open access
PDF file
KLKonstantinos Liapis
Konstantinos Liapis
GVGeorge Vrachiolias
George Vrachiolias
VPVasileios Papadopoulos
Vasileios Papadopoulos
AKAlexandra Kourakli
Alexandra Kourakli
AGAthanasios G. Galanopoulos
Athanasios G. Galanopoulos
IKIOANNIS KOTSIANIDIS
IOANNIS KOTSIANIDIS
Cardiovascular disease (CVD) emerges as a major cause of death in patients with myelodysplastic syndrome (MDS), but predictors of fatal CVD and the effect of MDS‐specific treatments on CVD mortality remain largely unknown. In an analysis involving 831 patients with MDS with known causes of death, we noted an independent association of lower risk MDS, age >70 years, pre‐existing CVD, and treatment with erythropoiesis‐stimulating agents with a higher risk of death from CVD. If externally validated, these simple risk factors could increase clinicians’ awareness toward CVD complications and guide early introduction of intensive monitoring and preventive interventions in MDS patients.

8 June 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
KLKonstantinos Liapis
Konstantinos Liapis
GVGeorge Vrachiolias
George Vrachiolias
ESEmmanouil Spanoudakis
Emmanouil Spanoudakis
IKIoannis Kotsianidis
Ioannis Kotsianidis

22 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
BMBouse Malkots
Bouse Malkots
ISIliana Stamatiou
Iliana Stamatiou
EPEmmanuil Panagiotopoulos
Emmanuil Panagiotopoulos
LILYDIA MARIA INGLEZOU
LYDIA MARIA INGLEZOU
VSVasiliki Sakka
Vasiliki Sakka
KLKonstantinos Liapis
Konstantinos Liapis
Clonal hematopoiesis refers to the clonal expansion of hematopoietic stem and progenitor cells, driven by somatic mutations. Major mutated genes in clonal hematopoiesis include genes involved in epigenetic regulation including DNA methylation and/or chromatin modification (e.g., DNMT3A, TET2, and ASXL1), tumor suppressors (e.g., TP53), signal transduction (e.g., JAK2), and RNA splicing (e.g., SF3B1 and SRSF2). Clonal hematopoiesis includes clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of unknown significance (CCUS), and myelodysplastic syndromes/neoplasms (MDS). CHIP occurs when the frequency of the variant allele equals or exceeds 2% (4% for X-linked genes in males) in the absence of cytopenias. CHIP is common among older persons and is associated with an increased risk of hematologic cancer. CHIP is also associated with an increased risk of atherosclerotic disease including acute myocardial infarction, stroke, cardiac failure, and abdominal aneurysm. Increasing evidence suggests that CHIP is associated with venous thromboembolic disease. Somatic mutations lead to proliferation of hematopoietic progenitor cells and their progeny, resulting in excessive activation of granulocytes and monocytes. It could be postulated that chronic inflammation caused by clonal expansion of myeloid cells carrying mutations in DNMT3A, TET2, and ASXL1 (“DTA”) genes may constitute an independent risk factor in clot formation and endothelial-cell damage. DTA mutations correlate with elevated proinflammatory cytokines such as IL-1β and IL-6 and enhanced activation of inflammasomes. Moreover, JAK2 mutations may have a direct role in the activation of platelets and coagulation. In vivo murine studies have demonstrated that activation of the JAK-STAT signaling pathway promotes neutrophil extracellular trap (NET) formation, contributing to a prothrombotic state. Insights from related clonal disorders such as paroxysmal nocturnal hemoglobinuria and the VEXAS syndrome support the concept that mutation-driven innate immune activation can directly perturb hemostatic balance. This review aims to summarize the association between clonal expansion of hematopoietic cells and thrombotic disease, and highlight how somatic mutations in hematopoietic cells may contribute to vascular disease and thrombogenesis.

15 May 2026 in Hematology Reports
Verified
Journal Article
Open access
PDF file
Ioannis TsamesidisIoannis Tsamesidis
Ioannis Tsamesidis
GDGEORGIOS DRYLLIS
GEORGIOS DRYLLIS
SVSotirios Varlamis
Sotirios Varlamis
NSNiki Smaragdaki
Niki Smaragdaki
PKPhilippos Klonizakis
Philippos Klonizakis
IPIlias Pessach
Ilias Pessach
Objectives: Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic disorders characterized by ineffective hematopoiesis, genomic instability, and a high risk of progression to acute myeloid leukemia. Oxidative stress (OS) has emerged as a central factor in MDS pathophysiology, contributing to DNA damage, altered cellular signaling, and disease progression. Recent advances in artificial intelligence (AI) and machine learning (ML) offer a transformative approach for integrating multidimensional datasets including oxidative stress markers, hematologic parameters, and molecular profiles to enhance diagnosis, prognostication, and therapeutic monitoring in MDS. Methods: A comprehensive literature search was conducted in PubMed and Scopus, using the keywords “OS biomarkers,” “AI,” and “MDS’’. Results: Modified redox biomarkers can be correlated with oxidative imbalance and disease progression. ML models such as neural networks, decision trees, and support vector machines effectively capture complex relationships among redox biomarkers, enhancing risk stratification and prediction of treatment response. AI-driven proteomic analyses further revealed OS-related protein signatures linked to MDS pathophysiology. Overall, AI and ML enable the transformation of multidimensional OS data into clinically actionable tools for personalized management in MDS. Conclusions: Integrating biomarker research with AI-based analytics holds promise for advancing personalized diagnostics, prognostication, and therapeutic strategies in MDS, paving the way toward precision medicine.

8 March 2026 in British Journal of Haematology
Verified
Journal Article
Open access
KLKonstantinos Liapis
Konstantinos Liapis
GKGeorgios Kanellis
Georgios Kanellis
GVGeorge Vrachiolias
George Vrachiolias
ECEvangelia Charitaki
Evangelia Charitaki